ENvue’s UroShield Secures UK NHS Reimbursement
ENvue Medical’s UroShield Kit is added to the NHS Drug Tariff Part IX, enabling nationwide reimbursement and triggering early commercial orders in the UK.
Industry Trends
Medline Raises $6.26B in 2025’s Biggest IPO
Medline has raised about $6.26B in an upsized IPO, surpassing CATL’s listing to become 2025’s largest debut.
CMS Reopens National TAVR Coverage Review at Edwards’ Request
CMS has accepted Edwards Lifesciences’ request to reopen the national coverage determination for TAVR, launching a review that could expand access to asymptomatic patients and ease procedural barriers by late 2026.
BMS Signs $1.1B Multispecific Antibody Deal With Harbour
Bristol Myers Squibb has entered a global collaboration with Harbour BioMed worth up to $1.1B to discover and develop next-generation multispecific antibodies, strengthening its early-stage immunology and oncology pipeline.
Genentech Strikes $1.1B Cancer AI Deal With Caris
Genentech has signed a multi-year oncology collaboration with Caris Life Sciences worth up to $1.1B, tapping the techbio’s AI-driven tumor database to discover new solid-tumor targets as year-end dealmaking accelerates.
ICER Backs Wegovy, Zepbound Value in Obesity but Flags Access Crunch
The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate. In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable … Read more
Zealand, OTR Sign Up to $2.5B Metabolic Drug Deal
Zealand Pharma’s up-to-$2.5B collaboration with OTR Therapeutics highlights a strategic pivot in metabolic drug development.
Yarrow Snags $1.37B TSHR Thyroid Drug From GenSci
Yarrow lands $1.37B China biotech deal, betting on first-in-class TSHR antibody for thyroid disease U.S.-based Yarrow Bioscience has secured its lead asset through a potential $1.37 billion licensing deal with China’s GenSci Pharmaceutical, picking up ex-China rights to a first-in-class antibody targeting autoimmune thyroid disease as it charts a broader expansion beyond its early platform … Read more
Sanofi stacks Alzheimer’s bet with second biotech deal of the day, lining up $1B-plus tau antibody pact
Sanofi has signed a global licensing agreement worth up to about $1.04 billion for an early-stage Alzheimer’s antibody targeting acetylated tau, marking the pharma’s second biotech deal of the day as it accelerates external pipeline building in neurology.
Dren Bio, Sanofi Expand $1.8B B-Cell Depletion Alliance
Dren Bio has expanded its strategic collaboration with Sanofi in a deal worth up to $1.8 billion, advancing next-generation B-cell depletion therapies and reinforcing deep-remission strategies in autoimmune disease.